Dr Mohammad Nasiruddin, Co-Ordinator, ADR Monitoring Centre confirmed that the notice was issued following an alert-notice from the Directorate of General of Health Services, Centre Drug Standard Control Organization, FDA Bhawan, New Delhi. “The drug is not approved in India for ophthalmic use by intra-vitrieal route,” said Dr Nasiruddin.
He added that it is requested that drug should not be used in ophthalmology to avoid such Serious Adverse Effect as directed by Directorate of General of Health Services, CDSCO, Ministry of Health and family Welfare, Government of India.
No comments:
Post a Comment